IP Library Patent Application 18910248
Patent Application
App. No. 18/910,248

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/910,248
Abstract

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Claims (22)

1 . A method for treatment of seizures associated with CDKL5 deficiency disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising about 50 mg/mL ganaxolone in a dosage regimen that comprises administering the pharmaceutical composition three times a day.

2 . The method of claim 1 , wherein the dosage regimen comprises starting at a low dose and escalating the dose.

3 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 0.001 mg/kg to about 10 mg/kg three times a day.

4 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 6 mg/kg three times a day.

5 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 11 mg/kg three times a day.

6 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 16 mg/kg three times a day.

7 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 21 mg/kg three times a day.

8 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 150 mg three times a day.

9 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 300 mg three times a day.

10 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 450 mg three times a day.

11 . The method of claim 1 , wherein the dosage regimen comprises a dose of about 600 mg three times a day.

12 . The method of claim 2 , wherein the dosage regimen comprises a dose of about 6 mg/kg three times a day.

13 . The method of claim 12 , wherein the dosage regimen further comprises a dose of about 11 mg/kg three times a day.

14 . The method of claim 12 , wherein the dosage regimen further comprises a dose of about 16 mg/kg three times a day.

15 . The method of claim 12 , wherein the dosage regimen further comprises a dose of about 21 mg/kg three times a day.

16 . The method of claim 2 , wherein the dosage regimen comprises a dose of about 150 mg three times a day.

17 . The method of claim 16 , wherein the dosage regimen further comprises a dose of about 300 mg three times a day.

18 . The method of claim 16 , wherein the dosage regimen further comprises a dose of about 450 mg three times a day.

19 . The method of claim 16 , wherein the dosage regimen further comprises a dose of about 600 mg three times a day.

20 . The method of claim 1 , wherein the pharmaceutical composition is administered orally.

21 . The method of claim 1 , wherein the frequency of seizures is reduced.

22 . The method of claim 1 , wherein the frequency of seizure is reduced, the severity of seizure is reduced, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2024
From: DURING, MATTHEW
To: OVID THERAPEUTICS INC.
Reel/Frame 068959/0202 →